KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
This study is recruiting at 22 US sites in 16 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors With HRAS Alterations
- Non Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Renal Cell Carcinoma (Kidney Cancer)
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Kura Oncology, Inc.
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Mayo Clinic Comprehensive Cancer Center · Phoenix, AZ
- University of Arizona · Tucson, AZ
California · 3
- Cedars-Sinai Medical Center · Los Angeles, CA
- UCLA Department of Medicine · Los Angeles, CA
- University of Southern California · Los Angeles, CA
Colorado · 1
- Sarah Cannon Research Institute at HealthONE · Denver, CO
Florida · 3
- AdventHealth Celebration · Celebration, FL
- Mayo Clinic Comprehensive Cancer Center · Jacksonville, FL
- Florida Cancer Specialists · Sarasota, FL
Iowa · 1
- University of Iowa Hospitals & Clinics · Iowa City, IA
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- Henry Ford Health System · Detroit, MI
Minnesota · 1
- Mayo Clinic Comprehensive Cancer Center · Rochester, MN
Missouri · 1
- Washington University School of Medicine · St Louis, MO
New Jersey · 1
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
Ohio · 1
- Ohio State University · Columbus, OH
Oklahoma · 1
- OU Stephenson Cancer Center · Oklahoma City, OK
Pennsylvania · 1
- UPMC Hillman Cancer Center · Pittsburgh, PA
Tennessee · 1
- SCRI - Oncology Partners · Nashville, TN
Texas · 2
- UT Southwestern Simmons Cancer Center · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
Wisconsin · 1
- University of Wisconsin (Carbone Cancer Center) · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.